在过去30年间，神经内分泌肿瘤(NET)的发病率提高约500%。以分子影像为指导的个体化治疗成为肿瘤诊疗学的核心。其需要有特异性的分子探针作为保障，而纳米技术为特异性分子探针提供了技术平台。核素标记的奥曲肽(Oc)是目前临床上应用最为广泛的NET诊疗试剂。本项目以糖基化的近红外核交联聚合胶束纳米粒子(NIRF-CCPM)为平台，将具有NET特异性的Oc与CCPM偶联，获得新型双重靶向(受体靶向/EPR效应)的纳米探针。而后进行64Cu标记，获得64Cu-NIRF-CCPM-Oc纳米探针，进行双模态(光学/核医学)显像、肿瘤双重治疗(Oc靶向治疗/核素放疗)的研究，并通过放射性自显影/免疫组化进行组织定位，进行影像学靶区和真实靶区比较。总之，64Cu-NIRF-CCPM-Oc的构建，将有效延长Oc的生物半衰期，通过双重靶向、双模态显像、双重治疗的研究，以达到NET早诊断、早治疗的目标。

In the past 30 years, the incidence of neuroendocrine tumors (NET) increases by about 500%. Molecular imaging guided individual treatment becomes the core of tumor therapy. It requires specific molecular probes, and nanotechnology-specific molecular probe provides a technology platform. Nuclide labeled octreotide (Oc) is currently the most widely used in clinical diagnosis reagent NET. This project take attestations to use glycosylation crosslinked polymeric micelles nanoparticles (NIRF-CCPM) as a platform, will have a specific octreotide coupled with CCPM, get di-targeting (receptor targeting / EPR effect ) nano-probes. Then , 64Cu used as a nuclide tracer, 64Cu-NIRF-CCPM-Oc nanoprobes will be prepared for dual-modality (optical/nuclear medicine) imaging, tumor dual therapy (Oc targeted therapy/ radionuclide radiation) research. Then, immunohistochemical/radiochemical were used for tissue localization, radiologic target and the real target comparison. In short, by the design of 64Cu-NIRF-CCPM-Oc nanoparticles, Octreotide will effectively extend the biological half-life, by the Double targeting, di-modality imaging and dual therapy NET in order to achieve early diagnosis, treatment of the tumors.